Veterinary Vaccine Market Size, Trends and Insights By Vaccine (Livestock Vaccine [Porcine Vaccines, Poultry Vaccines, Bovine Vaccines, Other Livestock Vaccines], Companion Animal Vaccine [Canine Vaccines, Equine Vaccines, Feline Vaccines], By Technology (Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Other Technologies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- MERCK
- Boehringer Ingelheim International GmbH
- Virbac
- Zoetis Services LLC
- Others
Reports Description
The “Global Veterinary Vaccine Market to 2030” was estimated at nearly USD 9 billion in 2021. As per our study, the market is anticipated to reach a value of USD 15 billion by 2030 showing a CAGR of 5%. Scrutinizing the uncertainties of the COVID-19 pandemic, our research team is constantly tracking and assessing the impact of the pandemic on the Veterinary Vaccine Market. These comprehensive insights are included in our market search report as a key market contributor.
The global Veterinary Vaccine Market research report offers an in-depth analysis of the global market size, which is further segmented into the regional and country-level market size, and segmentation market growth. Also, it provides the market share, sales analysis, competitive landscape, the impact of domestic and global market participants, trade regulations, value chain optimization, recent key developments, strategic market growth analysis, opportunities analysis, product launches, and technological innovations.
Veterinary Vaccine Market: Overview
Veterinary vaccines prevent the spread of diseases, protecting both the health of animals and people, which is crucial given the general public’s reliance on animals. Animals are a significant source of food, milk, protein, and other industrial goods like wool and leather. The most widely used veterinary vaccines for preventing the spread of infectious illnesses by imitating naturally acquired immunity include for rabies, foot-and-mouth disease, and equine influenza virus. With the introduction of more and more animal diseases, it is crucial that vaccinations continue to be developed. The rise in pet ownership has markedly enhanced the market’s expansion.
Veterinary Vaccine Market: COVID–19 Impact Analysis
The COVID-19 virus quickly spread around the world. Governments knew the virus was dangerous and posed a major threat when some of the victims died. Many people who made a full recovery either relapsed or suffered severe and ongoing health issues.
Pet owners and farmers were advised to keep their animals at home, which had a significant negative impact on the veterinary/animal immunizations industry. They were advised against giving their animals potent and efficient vaccinations, such as the Pfizer veterinary vaccines, at the vet’s office. Since a COVID-19 vaccine has been widely disseminated, the veterinary/animal immunizations industry is beginning to experience substantial growth. Since cattle on farms all around the world need vaccines to keep healthy, there is a strong need for animal vaccines.
Veterinary Vaccine Market: Growth Drivers
The Rise in the Pet Health Expenditure
The expansion of the market’s growth will be largely attributed to the rise in the occurrence of zoonotic and foodborne illnesses. The market for veterinary-animal vaccinations will develop as a result of an increase in supportive government initiatives and rising consumer demand for food products produced from animals. The market for veterinary-animal vaccines will expand at a faster rate as a result of other factors, including the rising trend of pet adoption and the rise in the need for animal protein in human food. Additionally, the market for veterinary animal vaccines will grow as a result of increased disposable income and changing lifestyles.
Surging investments in R&D
In the forecast period of 2022–2030, the increase in research and development activities aimed at creating an effective, efficient, and high-quality vaccine for farm and companion animals, as well as the introduction of new products, would favorably impact the veterinary-animal vaccines market.
Additionally, during the forecast period, technological developments in the creation of animal health vaccines and an increase in the number of emerging markets will create favorable opportunities for market growth for veterinary-animal vaccines. Additionally, the growth of cattle and poultry in developing nations, as well as advancements in medical technology, may accelerate the market for veterinary animal vaccinations in the coming years.
Veterinary Vaccine Market: Segmentation Analysis
The Veterinary Vaccine Market is segmented into vaccine type and technology. Based on the vaccine type, the canine vaccine segment dominated the global market for Veterinary Vaccines in 2021. Animals are typically protected from illnesses including the bluetongue virus, foot-and-mouth disease (FMD), and rabies with veterinary vaccines. However, due to the rising number of dogs kept as pets around the world, it is anticipated that demand for canine vaccination will expand quickly over the projection period. Since vaccination is one of the safest and most economical ways to prevent infectious disease, it has long been a cornerstone of canine treatment.
The segment has had considerable growth as a result of the rapid spread of canine vaccines, improvements in diagnostic procedures and vaccine technology, and worries about vaccine safety. Additionally, the market benefited by developing vaccination procedures as disease patterns and the pet population are constantly changing.
Report Scope
| Feature of the Report | Details |
| Market Size in 2021 | USD 9 Billion |
| Projected Market Size in 2030 | USD 15 Billion |
| CAGR Growth Rate | 5% CAGR (2022-2030) |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Prominent Players | MERCK, Boehringer Ingelheim International GmbH, Virbac, Zoetis Services LLC, Vetoquinol, Elanco, Ceva, Biovac, NEOGEN Corporation, ImmuCell Corporation, and Others |
| Key Segment | By Vaccine, Technology, and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors, and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfill your requirements for research. |
Key Insights:
- As per the analysis shared by our research analyst, the Veterinary Vaccine Market is estimated to grow annually at a CAGR of around 5% over the forecast period (2022-2030).
- In terms of revenue, the veterinary Vaccine Market size was valued at around USD 9 billion in 2021 and is projected to reach USD 15 billion by 2030. Due to a variety of driving factors, the market is predicted to rise at a significant rate.
- Based on vaccine segmentation, the livestock vaccines segment was estimated to show the maximum market share in the year 2021.
- Based on technology segmentation, the live attenuated vaccines segment was the leading revenue-generating category in 2021.
- On the basis of geography, the North American region was the leading revenue generator in 2021.
Recent Development
- August 2022:The Department of Animal Husbandry, Chandigarh Administration (India), has decided to start immunization in veterinary facilities because of the ongoing lumpy skin disease outbreak among cattle in Punjab and Haryana as well as rare instances being reported from Chandigarh.
- October 2020: Boehringer Ingelheim teamed up with Henke-Sass Wolf to create a novel intramuscular needle-free vaccine injection tool for pigs from the time of weaning till the conclusion of their nursery.
Regional Landscape
The largest market share is held by North America. The Animal and Plant Health Inspection Service’s Center for Veterinary Biologics (CVB) oversees the regulation of veterinary vaccinations in the United States (APHIS). Animal health companies are granted establishment and product licenses by the CVB in order to produce and market veterinary biologics.
The creation of non-replicating recombinant antigen vaccines, live vector vaccines, nucleic acid-mediated vaccines, as well as live-gene-deleted vaccinations are examples of developments in vaccine development in the United States. For instance, in January 2020, Zoetis, a renowned animal health business, added PoulvacProcerta HVT-ND, a vectored recombinant vaccine for defense against Newcastle and Marek’s disease viruses, to their chicken vaccine line-up.
The incidence of zoonotic diseases was significantly decreased by immunizing companion and wild animals against zoonotic diseases. The need for veterinary vaccinations in the region is also anticipated to increase as a result of technical improvements and growing awareness of disease prevention.
Competitive Landscape
The veterinary vaccines market has a number of significant competitors and is moderately competitive. The majority of these significant firms have a strong global footprint and are up against fierce rivalry in developing nations. Due to the market’s rapid expansion, which is being pushed by growing concerns about food safety and an increase in the adoption of companion animals, emerging nations are becoming hotspots for intense rivalry.
List of the prominent players in the global Veterinary Vaccine Market:
- MERCK
- Boehringer Ingelheim International GmbH
- Virbac
- Zoetis Services LLC
- Vetoquinol
- Elanco
- Ceva
- Biovac
- NEOGEN Corporation
- ImmuCell Corporation
The global Veterinary Vaccine Market is segmented as follows:
By Vaccine
- Livestock Vaccine
- Porcine Vaccines
- Poultry Vaccines
- Bovine Vaccines
- Other Livestock Vaccines
- Companion Animal Vaccine
- Canine Vaccines
- Equine Vaccines
- Feline Vaccines
By Technology
- Inactivated Vaccines
- Live Attenuated Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
- Other Technologies
On the basis of Geography
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market research methodology
- Chapter 2. Executive Summary
- 2.1 Global Veterinary Vaccine Market, (2022 – 2030) (USD Billion)
- 2.2 Global Veterinary Vaccine Market: snapshot
- Chapter 3. Global Veterinary Vaccine Market – Industry Analysis
- 3.1 Veterinary Vaccine Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Rise in the Pet Health Expenditure
- 3.2.2 Surging investments in R&D
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market attractiveness analysis By Vaccine
- 3.7.2 Market attractiveness analysis By Technology
- Chapter 4. Global Veterinary Vaccine Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Veterinary Vaccine Market: company market share, 2021
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, collaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Veterinary Vaccine Market – Vaccine Analysis
- 5.1 Global Veterinary Vaccine Market overview: By Vaccine
- 5.1.1 Global Veterinary Vaccine Market share, By Vaccine, 2021 and 2030
- 5.2 Livestock Vaccine
- 5.2.1 Global Veterinary Vaccine Market by Livestock Vaccine, 2022 – 2030 (USD Billion)
- 5.3 Companion Animal Vaccine
- 5.3.1 Global Veterinary Vaccine Market by Companion Animal Vaccine, 2022 – 2030 (USD Billion)
- 5.1 Global Veterinary Vaccine Market overview: By Vaccine
- Chapter 6. Global Veterinary Vaccine Market – Technology Analysis
- 6.1 Global Veterinary Vaccine Market overview: By Technology
- 6.1.1 Global Veterinary Vaccine Market share, By Technology, 2021 and 2030
- 6.2 Inactivated Vaccines
- 6.2.1 Global Veterinary Vaccine Market by Inactivated Vaccines, 2022 – 2030 (USD Billion)
- 6.3 Live Attenuated Vaccines
- 6.3.1 Global Veterinary Vaccine Market by Live Attenuated Vaccines, 2022 – 2030 (USD Billion)
- 6.4 Recombinant Vaccines
- 6.4.1 Global Veterinary Vaccine Market by Recombinant Vaccines, 2022 – 2030 (USD Billion)
- 6.5 Toxoid Vaccines
- 6.5.1 Global Veterinary Vaccine Market by Toxoid Vaccines, 2022 – 2030 (USD Billion)
- 6.6 Other Technologies
- 6.6.1 Global Veterinary Vaccine Market by Other Technologies, 2022 – 2030 (USD Billion)
- 6.1 Global Veterinary Vaccine Market overview: By Technology
- Chapter 7. Veterinary Vaccine Industry – Regional Analysis
- 7.1 Global Veterinary Vaccine Industry Regional Overview
- 7.2 Global Veterinary Vaccine Industry Share, by Region, 2021 & 2030 (USD Billion)
- 7.3. North America
- 7.3.1 North America Veterinary Vaccine Industry, 2022 – 2030 (USD Billion)
- 7.3.1.1 North America Veterinary Vaccine Industry, by Country, 2022 – 2030 (USD Billion)
- 7.3.1 North America Veterinary Vaccine Industry, 2022 – 2030 (USD Billion)
- 7.4 North America Veterinary Vaccine Industry, by Vaccine, 2022 – 2030
- 7.4.1 North America Veterinary Vaccine Industry, by Vaccine, 2022 – 2030 (USD Billion)
- 7.5 North America Veterinary Vaccine Industry, by Technology, 2022 – 2030
- 7.5.1 North America Veterinary Vaccine Industry, by Technology, 2022 – 2030 (USD Billion)
- 7.6. Europe
- 7.6.1 Europe Veterinary Vaccine Industry, 2022 – 2030 (USD Billion)
- 7.6.1.1 Europe Veterinary Vaccine Industry, by Country, 2022 – 2030 (USD Billion)
- 7.6.1 Europe Veterinary Vaccine Industry, 2022 – 2030 (USD Billion)
- 7.7 Europe Veterinary Vaccine Industry, by Vaccine, 2022 – 2030
- 7.7.1 Europe Veterinary Vaccine Industry, by Vaccine, 2022 – 2030 (USD Billion)
- 7.8 Europe Veterinary Vaccine Industry, by Technology, 2022 – 2030
- 7.8.1 Europe Veterinary Vaccine Industry, by Technology, 2022 – 2030 (USD Billion)
- 7.9. Asia Pacific
- 7.9.1 Asia Pacific Veterinary Vaccine Industry, 2022 – 2030 (USD Billion)
- 7.9.1.1 Asia Pacific Veterinary Vaccine Industry, by Country, 2022 – 2030 (USD Billion)
- 7.9.1 Asia Pacific Veterinary Vaccine Industry, 2022 – 2030 (USD Billion)
- 7.10 Asia Pacific Veterinary Vaccine Industry, by Vaccine, 2022 – 2030
- 7.10.1 Asia Pacific Veterinary Vaccine Industry, by Vaccine, 2022 – 2030 (USD Billion)
- 7.11 Asia Pacific Veterinary Vaccine Industry, by Technology, 2022 – 2030
- 7.11.1 Asia Pacific Veterinary Vaccine Industry, by Technology, 2022 – 2030 (USD Billion)
- 7.12. Latin America
- 7.12.1 Latin America Veterinary Vaccine Industry, 2022 – 2030 (USD Billion)
- 7.12.1.1 Latin America Veterinary Vaccine Industry, by Country, 2022 – 2030 (USD Billion)
- 7.12.1 Latin America Veterinary Vaccine Industry, 2022 – 2030 (USD Billion)
- 7.13 Latin America Veterinary Vaccine Industry, by Vaccine, 2022 – 2030
- 7.13.1 Latin America Veterinary Vaccine Industry, by Vaccine, 2022 – 2030 (USD Billion)
- 7.14 Latin America Veterinary Vaccine Industry, by Technology, 2022 – 2030
- 7.14.1 Latin America Veterinary Vaccine Industry, by Technology, 2022 – 2030 (USD Billion)
- 7.15. The Middle-East and Africa
- 7.15.1 The Middle-East and Africa Veterinary Vaccine Industry, 2022 – 2030 (USD Billion)
- 7.15.1.1 The Middle-East and Africa Veterinary Vaccine Industry, by Country, 2022 – 2030 (USD Billion)
- 7.15.1 The Middle-East and Africa Veterinary Vaccine Industry, 2022 – 2030 (USD Billion)
- 7.16 The Middle-East and Africa Veterinary Vaccine Industry, by Vaccine, 2022 – 2030
- 7.16.1 The Middle-East and Africa Veterinary Vaccine Industry, by Vaccine, 2022 – 2030 (USD Billion)
- 7.17 The Middle-East and Africa Veterinary Vaccine Industry, by Technology, 2022 – 2030
- 7.17.1 The Middle-East and Africa Veterinary Vaccine Industry, by Technology, 2022 – 2030 (USD Billion)
- Chapter 8. Company Profiles
- 8.1 MERCK
- 8.1.1 Overview
- 8.1.2 Financials
- 8.1.3 Product Portfolio
- 8.1.4 Business Strategy
- 8.1.5 Recent Developments
- 8.2 Boehringer Ingelheim International GmbH
- 8.2.1 Overview
- 8.2.2 Financials
- 8.2.3 Product Portfolio
- 8.2.4 Business Strategy
- 8.2.5 Recent Developments
- 8.3 Virbac
- 8.3.1 Overview
- 8.3.2 Financials
- 8.3.3 Product Portfolio
- 8.3.4 Business Strategy
- 8.3.5 Recent Developments
- 8.4 Zoetis Services LLC
- 8.4.1 Overview
- 8.4.2 Financials
- 8.4.3 Product Portfolio
- 8.4.4 Business Strategy
- 8.4.5 Recent Developments
- 8.5 Vetoquinol
- 8.5.1 Overview
- 8.5.2 Financials
- 8.5.3 Product Portfolio
- 8.5.4 Business Strategy
- 8.5.5 Recent Developments
- 8.6 Elanco
- 8.6.1 Overview
- 8.6.2 Financials
- 8.6.3 Product Portfolio
- 8.6.4 Business Strategy
- 8.6.5 Recent Developments
- 8.7 Ceva
- 8.7.1 Overview
- 8.7.2 Financials
- 8.7.3 Product Portfolio
- 8.7.4 Business Strategy
- 8.7.5 Recent Developments
- 8.8 Biovac
- 8.8.1 Overview
- 8.8.2 Financials
- 8.8.3 Product Portfolio
- 8.8.4 Business Strategy
- 8.8.5 Recent Developments
- 8.9 NEOGEN Corporation
- 8.9.1 Overview
- 8.9.2 Financials
- 8.9.3 Product Portfolio
- 8.9.4 Business Strategy
- 8.9.5 Recent Developments
- 8.10 ImmuCell Corporation
- 8.10.1 Overview
- 8.10.2 Financials
- 8.10.3 Product Portfolio
- 8.10.4 Business Strategy
- 8.10.5 Recent Developments
- 8.1 MERCK
List Of Figures
Figures No 1 to 21
List Of Tables
Tables No 1 to 52
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2030
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
FAQs
The “North America” region will lead the global Veterinary Vaccine market during the forecast period 2022 to 2030.
The expansion of the market’s growth will be largely attributed to the rise in the occurrence of zoonotic and foodborne illnesses. The market for veterinary-animal vaccinations will develop as a result of an increase in supportive government initiatives and rising consumer demand for food products produced from animals.
The key players operating in the Veterinary Vaccine market are MERCK, Boehringer Ingelheim International GmbH, Virbac, Zoetis Services LLC, Vetoquinol, Elanco, Ceva, Biovac, NEOGEN Corporation, ImmuCell Corporation, and Others.
The global Veterinary Vaccine market is expanding growth with a CAGR of approximately 5% during the forecast period (2022 to 2030).
The global Veterinary Vaccine market size was valued at USD 9 billion in 2021 and it is projected to reach around USD 15 billion by 2030.